The Radiation Therapy Oncology Group (RTOG) has launched a clinical trial to investigate the quality-of-life effects for prostate cancer patients who receive higher doses of radiation in fewer treatments.
Led by Dr. Himu Lukka, from the Juravinski Cancer Centre at McMaster University, the RTOG 0938 trial will assess outcomes of two hypofractionated radiotherapy (RT) regimens. Study participants will be randomized into one of two arms to receive a radiation dose of 36.25 Gy administered twice weekly for a total of five treatment sessions over 15 to17 days, or a dose of 51.6 Gy administered in 12 daily treatment sessions over 16 to 18 days. Target enrollment is 174 participants at RTOG sites across North America.
Favorable patient outcomes in this phase II trial will lead to a larger phase III trial to investigate the treatment strategy's therapeutic benefits, RTOG said.
